Mainz Biomed Reports Results of 2024 Annual General Meeting

Core Insights - Mainz Biomed N.V. held its Annual General Meeting on May 31, 2024, in Amsterdam, with 2,431,947 ordinary shares represented, constituting approximately 10.9% of outstanding shares [1] - All proposals presented at the meeting received requisite shareholder approval, including the adoption of statutory annual accounts and the reappointment of directors [1] Proposal Outcomes - Adoption of statutory annual accounts for the financial year ended December 31, 2023: 2,400,449 votes for, 22,528 against, 8,970 abstained [1] - Discharge from liability of directors for management during the financial year ended December 31, 2023: 2,187,602 votes for, 198,949 against, 45,396 abstained [1] - Amendment of articles of association: 2,344,801 votes for, 32,166 against, 54,980 abstained [1] - Extension of board's authorization to acquire ordinary shares: 2,229,837 votes for, 169,972 against, 32,138 abstained [1] - Reappointment of executive and non-executive directors received strong support, with votes for ranging from 2,368,376 to 2,378,154 [1] Nasdaq Compliance Update - Mainz Biomed is currently not in compliance with Nasdaq's minimum bid price requirement, as its ordinary shares have been below $1.00 for 30 consecutive trading days [2] - The company has been granted a 180-day compliance period to regain compliance, with a deadline of November 25, 2024 [2] - If compliance is not regained, the company may appeal Nasdaq's determination and request a hearing [2] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product, ColoAlert®, marketed across Europe [3] - The company plans to conduct a pivotal FDA clinical study for US regulatory approval and has a product candidate portfolio that includes PancAlert for pancreatic cancer screening [3]